This clinical trial is focused on studying Crohn’s Disease, a condition that causes inflammation in the digestive tract, leading to symptoms like abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The trial is testing a medication called Upadacitinib, also known by its code name ABT-494. This medication is taken as a modified-release tablet, which means it is designed to release the drug slowly over time. The study also includes a comparison with a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to evaluate the effectiveness and safety of Upadacitinib as a maintenance therapy for people with moderately to severely active Crohn’s Disease who have already responded to initial treatment with this medication in previous studies. The study is divided into two parts: the first part is a randomized, double-blind phase where participants will receive either Upadacitinib or a placebo to see how well the medication works in maintaining their health. The second part is a long-term extension to assess the ongoing safety and benefits of using Upadacitinib over a longer period.

Participants in the study will take the medication orally and will be monitored over time to see how their condition responds. The study aims to determine if Upadacitinib can help maintain clinical remission, which means keeping the symptoms of Crohn’s Disease under control, and to observe any potential side effects. The trial will also look at the impact of the medication on the need for hospitalizations and surgeries related to Crohn’s Disease. The study is expected to continue until 2027, providing valuable information on the long-term use of Upadacitinib for managing this chronic condition.